Evidence map›Paper›PMID 30637360›Full record

ArticleInvestigative and clinical urology2019

Transvaginal ultrasound guided trigone and bladder injection: A cadaveric feasibility study for a novel route of intradetrusor chemodenervation.

Raveen Syan, Mason A Briggs, John C Olivas, Sakti Srivastava, Craig V Comiter, Amy D Dobberfuhl

2 registry-linked trialsOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative and clinical urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05463822 early_phase1completednot on this map

Feasibility and Efficacy of Transvaginal Botulinum Toxin A Chemodenervation of the Bladder for the Third Line Treatment of Refractory Overactive Bladder

TypeinterventionalSponsorStanford UniversityRan2019 to 2021Enrolled15ConditionsOveractive Bladder, Bladder, Overactive, Urge Incontinence, Urgency UrinaryArmsTransvaginal botulinum toxin A (BTA) injection
NCT05485207 early_phase1unknown statusnot on this mapstarted 2022, after this paper: background citation

T3STOPBPS: Open Label Clinical Trial of Transvaginal Trigone Treatment (T3) With Botulinum Toxin A (BTA) for Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

TypeinterventionalSponsorStanford UniversityRan2022 to 2025Enrolled5ConditionsInterstitial Cystitis, Bladder Pain SyndromeArmsTransvaginal botulinum toxin A (BTA) injection
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Raveen SyanDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-4020-8004
Mason A BriggsDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
John C OlivasDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Sakti SrivastavaDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Craig V ComiterDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Amy D DobberfuhlDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · US

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationKL2TR001083 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$4.9M
TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007357 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 1986 to 2022
$4.8M
NCATS NIH HHS KL2 TR001083NIDDK NIH HHS T32 DK007357
6 · The paper itself

Abstract

purposeOnabotulinumtoxinA (BTX) detrusor chemodenervation is an efficacious third-line treatment for overactive bladder. Despite high clinical efficacy rates for BTX injection, many patients refuse initial or repeat treatment due to the invasiveness of the cystoscopic route of delivery. We assess the feasibility of injecting the trigone and posterior bladder wall via a transvaginal route under ultrasound guidance using a human cadaveric model. MATERIALS AND

methodsEight de-identified anonymous fresh female deceased donor cadaver pelvises were placed in supine split leg position. A transvaginal ultrasound probe guided injections of India ink into the trigone in 3 sites and the posterior wall in 2 sites. Full thickness bladder biopsies were then obtained and histologic analysis was performed to confirm presence of India ink in the detrusor layer.

resultsThe mean time from day of death was 11.0 days (range, 4.0-23.0 days). Three to five bladder biopsies were obtained per cadaver, for a total of 34 specimens (20 trigone, 14 posterior wall). Histologic analysis revealed presence of India ink within the detrusor layer in 8/8 (100.0%) of cadavers. The surgeon's perception of appropriate targeting under ultrasound guidance was confirmed in 8/8 cadavers (100.0%) involving the bladder trigone, and 7/8 (87.5%) involving the posterior wall. Of injections that were believed to have appropriately targeted the detrusor layer, 22/34 specimens (64.7%) demonstrated the presence of India ink under histologic analysis.

conclusionsIntradetrusor injection of the bladder trigone and posterior wall under transvaginal ultrasound guidance is feasible and has acceptable accuracy.

Indexed as

Administration, IntravesicalBotulinum Toxins, Type ACadaverEndosonographyFeasibility StudiesFemaleHumansNerve BlockProof of Concept StudyUltrasonography, InterventionalUrinary BladderUrinary Bladder, OveractiveVaginaBotulinum Toxins, Type Aonabotulinum toxin ABotulinum A toxinCadaverIntravesical injectionUltrasound imagingUrinary bladder, overactive

Identifiers

PMID30637360
PMCPMC6318206
OpenAlexW2907769843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.